Independent Director's 2025 Annual Work Report (Pang Jinwei)
Dear shareholders and shareholder representatives:
As the independent director of Chongqing Boten Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company"), I, Pang Jinwei, have strictly adhered to the relevant laws and regulations, including the Company Law of the People's Republic of China, the Management Measures for Independent Directors of Listed Companies, and the Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange No. 2 - Standardized Operations of Growth Enterprise Market Listed Companies, as well as the Company's Articles of Association and the Independent Director Work System. I have performed my duties honestly, diligently, and independently, actively attended relevant meetings, kept abreast of the Company's operational information, comprehensively monitored the Company's development status, carefully reviewed the board's proposals, fully exercised the independence and professionalism of independent directors, effectively safeguarded the legitimate interests of the Company and its shareholders, and contributed suggestions for the Company's long-term development. Below is my performance report for 2025:
1. Basic Information
I am Pang Jinwei, Ph.D. Currently, I serve as an independent director of the Company, associate professor at Shanghai National Accounting Institute, and director of the Digital Taxation Research Center. I am also an independent director of Shanghai Putailai New Energy Co., Ltd. and Hengxin Oriental Culture Co., Ltd. I do not hold any other positions in the Company apart from being an independent director, and I have no direct or indirect interests with the Company, controlling shareholders, or actual controllers that could hinder my independent and objective judgment. After self-examination, I meet the requirements for independent directors and have no circumstances affecting my independence, in compliance with the relevant requirements for independence stipulated in the Management Measures for Independent Directors of Listed Companies, the Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange No. 2, and the Company's Articles of Association and Independent Director Work System.
2. Meeting Attendance
The Company currently has three independent directors, meeting the requirement that independent directors account for one-third of the total number of directors.
(1) Meeting Attendance in 2025
The Company held a total of 8 board meetings and 2 shareholder meetings in 2025. The convening and holding of the board and shareholder meetings complied with legal procedures, and all significant operational decisions and other important matters followed the relevant procedures, making the meeting resolutions legal and effective. My attendance at the board and shareholder meetings is as follows: